Samantha Budd, Biogen, Boston, USA
Samantha Budd Haeberlein is Vice President and Clinical Development Unit Head at Biogen, Cambridge, MA, USA. As part of Biogen she leads the Late Stage Unit accountable for the Clinical Development of Biogen’s portfolio for Alzheimer’s disease, dementia, and movement disorders. Budd Haeberlein has nearly 20 years of biopharmaceutical industry experience across research, translational medicine, and clinical development. Before Biogen, Budd Haeberlein was at AstraZeneca, where she held roles in the USA, Canada, and Sweden as Vice President of Translational Science & Global Programme Lead in Alzheimer’s disease. Budd Haeberlein is a member of the World Dementia Council and an executive board member of The Boston Home and has a BSc and a PhD degree in biochemistry from the University of Dundee. She was an instructor at Harvard Medical School, Boston, MA, USA and did research at The Burnham Institute, San Diego, CA, USA before joining the biopharmaceutical industry.
« Go Back